Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.

Discover more from RealUS.news

Subscribe now to keep reading and get access to the full archive.

Continue reading